| Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients (NCT01565746) | Bayer | 2012-03-01 |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (NCT01522443) | Exelixis | 2012-03-01 |
| AMG 386 and Abiraterone for Advanced Prostate Cancer (NCT01553188) | National Cancer Institute (NCI) | 2012-02-08 |
| Vascular Changes Of Patients Undergoing Laparoscopic Radical Prostatectomy (NCT03241758) | Corporacion Parc Tauli | 2011-11-29 |
| MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness (NCT01464216) | Oslo University Hospital | 2011-10-01 |
| Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer (NCT01446731) | Inge Marie Svane | 2011-10-01 |
| Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer (NCT01441713) | Copenhagen University Hospital at Herlev | 2011-09-01 |
| MR Image Guided Therapy in Prostate Cancer (NCT01377753) | National Cancer Institute (NCI) | 2011-08-12 |
| Evaluation of Modern MRI in the Diagnosis of Prostate Cancer in a Danish Setup (NCT01640262) | Copenhagen University Hospital at Herlev | 2011-08-01 |
| Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer (NCT01335204) | Medical University of South Carolina | 2011-06-01 |
| A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (NCT01545882) | Ottawa Hospital Research Institute | 2011-05-01 |
| Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy (NCT01365143) | Mayo Clinic | 2011-05-01 |
| Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer (NCT01357512) | University of Oulu | 2011-04-01 |
| A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer (NCT01288911) | Astellas Pharma Inc | 2011-03-22 |
| Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations (NCT01955863) | Wesley Justino Magnabosco | 2011-03-01 |
| A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (NCT01306890) | Dendreon | 2011-01-27 |
| Testing Decision Aids About Early Stage Prostate Cancer (NCT02053389) | University of Michigan | 2010-11-01 |
| Vitamin C as an Anti-cancer Drug (NCT01080352) | Copenhagen University Hospital at Herlev | 2010-11-01 |
| Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 (NCT01132404) | Millennium Pharmaceuticals, Inc. | 2010-11-01 |
| Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression (NCT01653925) | CHU de Quebec-Universite Laval | 2010-10-28 |
| Study to Find Maintenance Dose for Periodic Administration of ASP3550 (NCT01261572) | Astellas Pharma Inc | 2010-10-12 |
| Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy (NCT01450683) | Stanford University | 2010-09-01 |
| Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Versus Radical Retropubic Prostatectomy (NCT01173952) | Samsung Medical Center | 2010-08-01 |
| CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS) (NCT01206036) | Central European Society for Anticancer Drug Research | 2010-07-01 |
| A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer (NCT01095848) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2010-03-01 |
| Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator (NCT00999960) | Assistance Publique - Hôpitaux de Paris | 2010-02-01 |
| Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients (NCT01076751) | Sanofi | 2010-02-01 |
| Aggressive Prostate Cancers in Elderly Patients (NCT01347476) | Seoul National University Hospital | 2010-01-01 |
| Symptoms and Quality of Life (QoL) After Palliative Pelvic Radiation of Prostate and Rectal Cancers (NCT01023529) | Sorlandet Hospital HF | 2009-11-01 |
| Figitumumab Combined With Pegvisomant For Advanced Solid Tumors (NCT00976508) | Pfizer | 2009-11-01 |
| Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer (NCT01020305) | Sandy Srinivas | 2009-10-01 |
| Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result (NCT01024959) | Gen-Probe, Incorporated | 2009-08-01 |
| Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer (NCT00906269) | Hartford Hospital | 2009-07-01 |
| Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors (NCT00962494) | Stanford University | 2009-07-01 |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration (NCT00878436) | NYU Langone Health | 2009-06-01 |
| Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF) (NCT00917748) | Sanofi | 2009-06-01 |
| Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer (NCT00900614) | Aprea Therapeutics | 2009-05-01 |
| Test Semiquantitative Prostate Specific Antigen (PSA) (NCT00853710) | Institut Curie | 2009-03-01 |
| Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment (NCT01198457) | Bayer | 2009-01-01 |
| Evaluation of MRI for Prostate Cancer (NCT00930748) | Sheba Medical Center | 2008-11-01 |
| Prostate Mechanical Imager (PMI) Clinical Bridging Study (NCT00822952) | Artann Laboratories | 2008-10-01 |
| Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer (NCT00844792) | University Health Network, Toronto | 2008-10-01 |
| Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer (NCT00744497) | Bristol-Myers Squibb | 2008-10-01 |
| Prostate Active Surveillance Study (NCT00756665) | University of Washington | 2008-07-01 |
| Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance (NCT00744549) | University Health Network, Toronto | 2008-05-01 |
| Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy (NCT00638690) | Cougar Biotechnology, Inc. | 2008-05-01 |
| Safety Study of TAK-700 in Subjects With Prostate Cancer. (NCT00569153) | Millennium Pharmaceuticals, Inc. | 2008-04-01 |
| A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer (NCT00672009) | Cedars-Sinai Medical Center | 2008-04-01 |
| An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer (NCT00748358) | Assistance Publique - Hôpitaux de Paris | 2008-03-01 |
| Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy (NCT00593853) | University Health Network, Toronto | 2008-01-01 |
| CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution (NCT00643994) | Accuray Incorporated | 2007-12-01 |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer (NCT00564928) | Infinity Pharmaceuticals, Inc. | 2007-11-01 |
| CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry (NCT00643617) | Accuray Incorporated | 2007-10-22 |
| Phase II Study of ASP3550 in Patients With Prostate Cancer (NCT00568516) | Astellas Pharma Inc | 2007-10-01 |
| Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer (NCT00521781) | The Methodist Hospital Research Institute | 2007-08-01 |
| Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer (NCT00521274) | The Methodist Hospital Research Institute | 2007-08-01 |
| Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (NCT00519285) | Sanofi | 2007-08-01 |
| PK in Pts With HRPC & Skeletal Metastes (NCT00667537) | Bayer | 2007-07-01 |
| A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA) (NCT00514917) | Sanofi | 2007-07-01 |
| Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression (NCT00446901) | Wageningen University | 2007-06-01 |
| HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer (NCT01913106) | The Methodist Hospital Research Institute | 2007-06-01 |
| An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer (NCT00537381) | Centocor, Inc. | 2007-05-01 |
| The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study (NCT00452556) | Nova Scotia Cancer Centre | 2007-05-01 |
| Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer (NCT00546039) | University Hospital, Aker | 2007-04-01 |
| A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. (NCT00378482) | AstraZeneca | 2007-03-05 |
| Collection of Blood From Patients With Prostate Cancer (NCT00923221) | National Cancer Institute (NCI) | 2007-02-28 |
| Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance (NCT00482157) | Stanford University | 2007-02-01 |
| Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy (NCT00448097) | The Methodist Hospital Research Institute | 2007-02-01 |
| XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (NCT00417079) | Sanofi | 2007-01-01 |
| Taxotere Prostate Cancer New Indication Registration Trial in China (NCT00436839) | Sanofi | 2007-01-01 |
| Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer (NCT00450008) | The Methodist Hospital Research Institute | 2006-12-01 |
| Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer (NCT00381836) | University of Aarhus | 2006-10-01 |
| Phase II Study of BI 2536 in Prostate Cancer (NCT00706498) | Boehringer Ingelheim | 2006-09-01 |
| Fulvestrant in Hormone Refractory Prostate Cancer (NCT00476645) | Stanford University | 2006-09-01 |
| Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer (NCT00705822) | Sanofi | 2006-08-01 |
| Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer (NCT00477087) | Stanford University | 2006-07-01 |
| Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer (NCT00447473) | The Methodist Hospital Research Institute | 2006-07-01 |
| Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer (NCT00448409) | The Methodist Hospital Research Institute | 2006-05-01 |
| A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer (NCT00706628) | Boehringer Ingelheim | 2006-03-01 |
| MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011) (NCT00302471) | Merck Sharp & Dohme LLC | 2006-03-01 |
| A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer (NCT00271687) | AHS Cancer Control Alberta | 2006-02-01 |
| The Effects of Lycopene on High Risk Prostatic Tissue (NCT01443026) | University of Illinois at Chicago | 2006-02-01 |
| Docetaxel in the Treatment of Hormone Refractory Prostate Cancer (NCT00280098) | Sanofi | 2006-01-01 |
| Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging - Protocol II (NCT00250224) | Aalborg University Hospital | 2006-01-01 |
| Far Infrared Radiation Treatment for Prostate Cancer (NCT00573820) | GAAD Medical Research Institute Inc. | 2006-01-01 |
| Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy (NCT00283062) | Sanofi | 2005-12-01 |
| A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer (NCT02182063) | Boehringer Ingelheim | 2005-11-01 |
| A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy (NCT00473512) | Cougar Biotechnology, Inc. | 2005-11-01 |
| Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer (NCT02182219) | Boehringer Ingelheim | 2005-11-01 |
| Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer (NCT00137436) | Pfizer | 2005-10-01 |
| A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer (NCT00401765) | Centocor, Inc. | 2005-09-01 |
| Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer (NCT00121095) | Cytogen Corporation | 2005-07-01 |
| Vaccine and Antibody Treatment of Prostate Cancer (NCT00113984) | National Cancer Institute (NCI) | 2005-06-08 |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer (NCT00861471) | NYU Langone Health | 2005-05-01 |
| Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer (NCT00089609) | National Cancer Institute (NCI) | 2005-04-19 |
| Cone Beam CT for Daily Image Guidance - Prostate Cancer (NCT00188786) | University Health Network, Toronto | 2005-04-01 |
| Gene Therapy for Prostate Cancer That Returns After Radiation Therapy (NCT00110526) | Simon Hall | 2005-04-01 |
| Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer (NCT00489905) | Hospital Authority, Hong Kong | 2005-04-01 |
| Efficacy and Safety Study of Xyotax to Treat Prostate Cancer (NCT00446836) | The Methodist Hospital Research Institute | 2005-03-01 |
| A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer (NCT00383487) | Stanford University | 2005-03-01 |